Poland· PL-100121120
Normatens
A other antihypertensives and diuretics product containing clopamidum + dihydroergocristinum + reserpinum, registered in Poland by Delfarma Sp. z o.o..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Clopamidum + Dihydroergocristinum + Reserpinum
- Manufacturer
- Delfarma Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- C02LX
- ATC class
- Other antihypertensives and diuretics
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991238186
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under C02LX
Other antihypertensives and diuretics, as other registers publish it.
- PolandNormatensInPharm Sp. z o.o.
- PolandNormatensBausch Health Ireland Ltd.
- PolandNormatensMedezin Sp. z o.o.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Latvia · Normatens
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f0375c54-5a79-48ab-ae55-ea0ce4afd298 GET /v1/drugs/f0375c54-5a79-48ab-ae55-ea0ce4afd298?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki drażowane",
"source": "urpl",
"strength": "5 mg + 0,5 mg + 0,1 mg",
"packaging": "05909991238186 ¦ Rp ¦ 111070\n20 tabl.",
"substance": "Clopamidum 5 mg + Dihydroergocristinum 0.5 mg + Reserpinum 0.1 mg + Peginterferonum alfa-2b 150 mcg",
"common_name": "Clopamidum + Dihydroergocristinum + Reserpinum",
"pl_product_id": "100121120",
"pozwolenie_nr": "627/15",
"auth_procedure": "IR",
"authorisation_validity": "2030-09-15"
}See everything about clopamidum + dihydroergocristinum + reserpinum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.